Heron Therapeutics (HRTX) Construction in Progress (2011 - 2025)

Heron Therapeutics (HRTX) has reported Construction in Progress for 13 consecutive years, with $1.7 million the latest figure, recorded in Q4 2025.

• For the quarter ending Q4 2025, Construction in Progress fell 34.62% year-over-year to $1.7 million; the trailing twelve-month figure through Dec 2025 stood at $1.7 million (down 34.62% YoY), and the FY2025 full-year result was $1.7 million, down 34.62% from the prior year.
• Construction in Progress retreated to $1.7 million in Q4 2025 per HRTX's latest filing, from $2.6 million in the prior quarter.
• Across five years, Construction in Progress topped out at $15.9 million in Q4 2021 and bottomed at $1.7 million in Q4 2025.
• Historically, Construction in Progress has averaged $6.4 million across 5 years, with a median of $5.4 million in 2022.
• The sharpest annual moves came in 2022 and 2023: Construction in Progress tumbled 66.04% in 2022, then advanced 16.67% in 2023.
• Over 5 years, Construction in Progress stood at $15.9 million in 2021, then plunged by 66.04% to $5.4 million in 2022, then advanced by 16.67% to $6.3 million in 2023, then plunged by 58.73% to $2.6 million in 2024, then sank by 34.62% to $1.7 million in 2025.
• According to Business Quant data, Construction in Progress over the past three periods registered $1.7 million, $2.6 million, and $6.3 million for Q4 2025, Q4 2024, and Q4 2023 respectively.